Industry · Pharmaceutical
Pharma is confronting a historic patent cliff, a surging M&A cycle, the GLP-1 boom, AI across R&D and new Medicare price negotiation — all at once. For the companies that sell to it, that means scientific, highly regulated, multi-stakeholder buying. Coral Blue Data helps you find the right pharma and life-sciences accounts and fuel demand and lead generation that fits how the industry buys today.
Pharmaceutical industry trends 2026
Across analyst outlooks, deal trackers and policy briefings, the same themes keep surfacing. Each one changes what pharma and life-sciences companies buy, who signs off and how long it takes.
Branded pharma revenue set to lose patent protection by 2030
Blockbusters including Keytruda, Eliquis and Opdivo face loss of exclusivity, putting a large share of some companies' sales at risk and forcing an urgent hunt for new revenue.
So what: pharma is investing hard in pipeline, deals and efficiency to fill the gap.
Projected biopharma M&A deal value in 2026
With the cliff approaching, big pharma is acquiring assets and biotechs to rebuild pipelines. IQVIA expects aggregate 2026 deal value of $140-160B, with upside beyond that.
So what: consolidation reshapes accounts, buyers and budgets, sometimes overnight.
Source: IQVIA Biopharma M&A Outlook 2026
Projected global GLP-1 market in 2026, up from about $66B in 2025
Metabolic medicines are the industry's fastest-growing engine, with obesity therapies alone forecast to add around $100B in sales by 2029 and reshaping commercial priorities.
So what: commercial, manufacturing and supply investment is pouring into metabolic therapies.
Pharma companies that have implemented AI in at least one workflow, led by drug discovery
AI adoption is highest in discovery and clinical development, where it promises to shorten timelines and cut costs — a direct response to the pressure on pipelines.
So what: R&D and data buyers want proven, compliant AI, not experiments.
Discounts on the first 10 Medicare-negotiated drug prices, effective January 2026
The Inflation Reduction Act's negotiated prices take effect in 2026, with more drugs to follow. Pricing risk is now a factor in development and commercial decisions.
So what: market-access, pricing and evidence needs rise across the commercial model.
Projected global medicine spending by 2030, growing 5-8% a year; US spending passes $1T in 2026
Despite policy and patent headwinds, global medicine use keeps rising, led by oncology, immunology and metabolic therapies — sustaining investment across the value chain.
So what: the market is growing, but spend is concentrating in a few therapy areas.
Source: IQVIA Institute 2026 Forecast
Adoption clusters in drug discovery and clinical development — exactly the functions racing to replace cliff-exposed revenue. Regulatory and compliance lag, leaving room for vendors who can prove rigour.
So what: meet R&D buyers with evidence, validation and a compliance story.
Source: IntuitionLabs, 2026 benchmarks
AI adoption across pharma, by function (2026)
Last updated: November 2026
What it means for you
Investment is strong, but buying is scientific, highly regulated and spread across many stakeholders. Consolidation keeps moving the targets, and buyers expect you to understand compliance and the science. Growth now depends on precision and credibility.
R&D, medical and commercial stakeholders expect depth, data and proof — generic pitches do not survive first contact.
Privacy, validation and promotional rules shape every interaction, especially around patient and prescriber data.
The M&A wave reshuffles accounts, decision-makers and budgets, making account data go stale fast.
Oncology, immunology and metabolic areas absorb much of the growth, so targeting the right franchise matters.
Medicare negotiation and global pricing scrutiny push buyers to demand clear value and market-access evidence.
Decisions cross R&D, commercial, regulatory, IT and procurement — reaching one champion is never enough.
Questions pharma growth teams are asking
How we help
In pharma, these three only work when they build on each other. Accurate account data shows you where to play; demand generation earns attention from scientific and commercial stakeholders; lead generation turns that attention into qualified conversations.
Step 1 · Data
"Where should we focus?"
Step 2 · Demand generation
"How do we get on their radar?"
Step 3 · Lead generation
"Who do we talk to this week?"
Coral Blue Data provides the life-sciences data foundation — accounts, contacts, enrichment and hygiene — that powers your demand and lead generation programmes, whether you run them in-house or with an agency. Talk with a life-sciences data expert →
Buyer personas
These personas represent the teams that sell into pharma and life sciences most often. Each faces a different version of the 2026 market. Here is how data, demand generation and lead generation change the outcome for each.
Head of Growth · Real-world data & commercial analytics
Goal
Win pharma accounts that need better data to defend revenue through the cliff.
What they're facing
How we help
Segment pharma and biotech by size, therapy focus and function; reach commercial, data and market-access leaders.
Run ABM with evidence and ROI content for scientific and commercial buyers.
Keep target lists current through consolidation and reorganisation.
Outcome: pipeline aimed at the right franchises, kept accurate through the M&A wave.
VP Sales · Clinical research & trial services
Goal
Win clinical and development work as pharma races to refill pipelines.
What they're facing
How we help
Reach R&D, clinical operations and development leaders by therapy area and company stage.
Share speed, quality and efficiency content with scientific and procurement buyers.
Prioritise sponsors with active pipelines matched to your capabilities.
Outcome: conversations with sponsors whose programmes fit what you do best.
Head of Marketing · AI drug-discovery & R&D platforms
Goal
Land pharma R&D teams ready to adopt AI to shorten discovery and development.
What they're facing
How we help
Target by therapy focus and R&D maturity; reach discovery, informatics and data-science leaders.
Share validated results and compliance-ready content with scientific buyers.
Prioritise teams with the data and intent to move beyond pilots.
Outcome: outreach that stands out in a noisy category and reaches teams ready to adopt.
Business Development · Manufacturing & supply services
Goal
Win manufacturing and supply work as GLP-1 and biologics demand surges.
What they're facing
How we help
Reach supply-chain, manufacturing and procurement leaders by modality and therapy area.
Lead with capacity, quality and reliability content for technical and procurement buyers.
Focus on sponsors scaling the therapies where you have capacity.
Outcome: a pipeline matched to where capacity demand is growing fastest.
VP Growth · Market access, med-comms & HCP engagement
Goal
Help pharma launch and defend brands under pricing and access pressure.
What they're facing
How we help
Reach commercial, market-access and medical-affairs leaders by therapy area and brand stage.
Support launch, access and HCP-engagement programmes with precise, permission-aware audiences.
Point teams at the brands and franchises where you add most value.
Outcome: commercial teams aligned on the same high-value brands and stakeholders.
Personas are illustrative composites based on common pharma and life-sciences go-to-market teams, not specific individuals.
The pharma buying group
Most pharma purchases now pass through several hands across science, commercial and compliance. Effective demand and lead generation speaks to each of them in their own terms.
Discovery, development and informatics leaders judge scientific value and fit.
Brand, commercial and access leaders weigh launch impact, pricing and payer strategy.
Regulatory, quality and legal teams assess validation, privacy and promotional rules.
CIOs and data leaders assess integration, data governance and vendor risk.
Sourcing teams compare terms, alternatives and supplier risk across the organisation.
The most discussed trends are a $300B+ patent cliff, a large M&A cycle to replenish pipelines, the GLP-1 and obesity boom, AI spreading across R&D, and Medicare price negotiation taking effect — all against still-growing global medicine demand.
Buying is scientific, highly regulated and spread across R&D, commercial, regulatory, IT and procurement. Expect long cycles, a compliance bar on most interactions, and account data that shifts quickly as consolidation continues.
The patent cliff is the wave of blockbuster drugs losing market exclusivity, exposing more than $300B of branded revenue to biosimilar and generic competition by 2030 and driving pharma to invest heavily in new pipeline and deals.
Demand generation creates interest across your target market. Lead generation captures and qualifies specific accounts and people ready for a sales conversation. In pharma, both depend on accurate, compliant account and contact data.
Start by mapping target accounts and their full buying group across science, commercial and compliance. Then tailor messages by role — evidence for R&D, ROI for commercial, validation for regulatory — and stay visible, and compliant, through long evaluations.
We supply the life-sciences data foundation: account and contact data for pharma, biotech and the companies that serve them, plus enrichment, cleansing and verification to keep it current for your campaigns and outreach.
Tell us who you sell to and what you're trying to grow. We'll show you the pharma and life-sciences accounts and buying groups that fit, and how to put that data to work in your demand and lead generation.
A specialist reviews every request and replies by email, typically within two business days.
Sources
